Drug shortage
Sodium Bicarbonate Injection · Hospira, Inc., a Pfizer Company
FDA drug shortage · Current · updated Apr 11, 2025
Key facts
| Generic name | Sodium Bicarbonate Injection |
|---|---|
| Proprietary name | Sodium Bicarbonate |
| Company | Hospira, Inc., a Pfizer Company |
| Presentation | Sodium Bicarbonate, Injection, 2.5 mEq/5 mL (4.2%, 0.5 mEq/mL) (NDC 0409-5555-01) |
| Dosage form | Injection |
| Strength | 2.5 mEq/5 mL (4.2%, 0.5 mEq/mL) |
| Status | Current |
| Therapeutic category | Endocrinology/Metabolism Gastroenterology Pediatric |
| Package NDCs | 0409-5555-01 |
| First posted | Mar 1, 2017 |
| Last updated | Apr 11, 2025 |
At a glance
- 1–9 Package NDCs affected
- 10–99 FDA shortage records for this drug
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA drug shortages
The FDA Drug Shortages Database lists current and resolved shortages of drugs, with presentations, affected NDCs and reasons reported by manufacturers.
Source: U.S. Food and Drug Administration (FDA), Drug Shortages Database · Source date: